EU/ACP/WHO Renewed Partnership
Strengthening pharmaceutical systems and improving access to quality medicines in 15 African countries
From 2004 to 2010, the first EC/ACP/WHO Partnership on Pharmaceutical Policies (PPP) was instrumental to provide strategic and technical support for the development and implementation of essential medicines policies in African, Caribbean and Pacific Island countries (ACP). Based on the findings and recommendations from the PPP end of programme evaluation, the WHO Essential Medicines and Health Products Department and the European Commission (EC) agreed to undertake an “EU/ACP/WHO Renewed Partnership to strengthen pharmaceutical systems and improve access to quality medicines in 15 African ACP countries” starting 1st October 2012 and for a duration of 4 years ( 2012-2016).
The overall objective is to contribute to the achievement of health-related MDGs and of universal health coverage in African ACP countries by improving availability, affordability and use of quality-assured essential medicines for priority acute and non-communicable diseases thereby contributing to improved cost-effective health care and better patient health outcomes.
The Renewed Partnership will focus on the implementation of policies, enforcement of regulations and adoption of best practices and on strengthening pharmaceutical systems. The 5 areas of work (or results areas) are:
Areas of work
- Result Area 1: Improved availability and supply of essential medicines in national, regional and community health facilities in African ACP countries;
- Result Area 2: Lower medicines prices and improved mechanisms for financing and for coverage of essential medicines in social protection schemes;
- Result Area 3: Improved quality and safety of medicines and reduced occurrence of substandard medicines and of medicines that pose health risks;
- Result Area 4: Improved medicines selection, prescribing, dispensing and use;
- Result Area 5: Improved access to reliable information of pharmaceutical sector and policy of countries; review of evidence based national medicines policies and plans; enhanced transparency and good governance of the pharmaceutical sector.